Journal of Clinical Endocrinology & Metabolism, Vol 75, 865-870, Copyright © 1992 by Endocrine Society

ARTICLES

Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line

M Thomas and JD Monet
Laboratoire TIM3-USR CNRS B690/Equipe de Reconnaissance des Formes et Microscopie Quantitative, Universite Joseph Fourier, Grenoble, France.

The antiproliferative effect of RU486 and its effect combined with tamoxifen on the growth and cell cycle kinetics parameters on the MCF-7 human carcinoma cells were investigated. When MCF-7 cells in the exponential growth phase were treated with RU486 (10(2) nmol/L), a time- dependent cell growth inhibition was observed which was significant 5 days after the beginning of treatment. This inhibition was accompanied by a time- and dose-dependent decrease in the percentage of S and G2-M phase cells and a concomitant increase in the percentage of cells in the G0/G1 phase of the cell cycle. With tamoxifen (10(5) pmol/L), growth inhibition was obtained after 4 days of treatment of cells, and the blockage of the cell cycle occurred in the G0/G1 phase. In the case of simultaneous treatment of MCF-7 cultures with RU486 (10(2) nmol/L) and tamoxifen (10(5) pmol/L), we observed a synergistic inhibitory effect on the proliferative rate for short treatment (less than or equal to 3 days), whereas RU486 or tamoxifen alone had no effect. For the intermediate treatment (4 days), the combined effect of RU486 and tamoxifen was not significant compared to the effect of tamoxifen alone. For the long treatment (greater than 4 days), there were no differences between the number of cells in the treated cultures under different experimental conditions, but all were inhibited compared to those in control cell cultures. This simultaneous treatment of cells does not induce any change in the distribution of cells in the different cell cycle phases compared to tamoxifen percentages. These results suggest that RU486 is a cell cycle phase-specific growth inhibitory agent, and a combination of antiestrogen/antiprogestin should be considered as a possible improvement in breast cancer endocrine therapy.

This article has been cited by other articles:

				B. G. MOE, A. B. VEREIDE, A. ORBO, and G. SAGER High Concentrations of Progesterone and Mifepristone Mutually Reinforce Cell Cycle Retardation and Induction of Apoptosis Anticancer Res, April 1, 2009; 29(4): 1053 - 1058. [Abstract] [Full Text] [PDF]

				V. T. Gaddy, J. T. Barrett, J. N. Delk, A. M. Kallab, A. G. Porter, and P. V. Schoenlein Mifepristone Induces Growth Arrest, Caspase Activation, and Apoptosis of Estrogen Receptor-Expressing, Antiestrogen-Resistant Breast Cancer Cells Clin. Cancer Res., August 1, 2004; 10(15): 5215 - 5225. [Abstract] [Full Text] [PDF]

				T. A. Jackson, J. K. Richer, D. L. Bain, G. S. Takimoto, L. Tung, and K. B. Horwitz The Partial Agonist Activity of Antagonist-Occupied Steroid Receptors Is Controlled by a Novel Hinge Domain-Binding Coactivator L7/SPA and the Corepressors N-CoR or SMRT Mol. Endocrinol., June 1, 1997; 11(6): 693 - 705. [Abstract] [Full Text]

				N. Guthrie, A. Gapor, A. F. Chambers, and K. K. Carroll Inhibition of Proliferation of Estrogen Receptor-Negative MDA-MB-435 and -Positive MCF-7 Human Breast Cancer Cells by Palm Oil Tocotrienols and Tamoxifen, Alone and in Combination J. Nutr., March 1, 1997; 127(3): 544 - 544. [Abstract] [Full Text]

				E. A. Musgrove, C. S. L. Lee, A. L. Cornish, A. Swarbrick, and R. L. Sutherland Antiprogestin Inhibition of Cell Cycle Progression in T-47D Breast Cancer Cells Is Accompanied by Induction of the Cyclin-Dependent Kinase Inhibitor p21 Mol. Endocrinol., January 1, 1997; 11(1): 54 - 66. [Abstract] [Full Text]